SCHEMBL25321380

SCHEMBL25321380

CC(F)(F)c1nc2ccc(Br)cc2[nH]c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ POLB P06746 1/20 0.48
▸ PABPC1 P11940 1/20 0.48
▸ KDM4E B2RXH2 3/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ KHK P50053 1/20 0.48
▸ EGFR P00533 1/20 0.47
▸ HTT P42858 2/20 0.45
▸ LMNA P02545 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ TYMS P04818 2/20 0.43
▸ TRPV1 Q8NER1 1/20 0.42
▸ MMP2 P08253 4/20 0.41
▸ MMP9 P14780 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30493593 1.00 MAPT (0.48) MAPTMEN1KMT2APOLBPABPC1
SCHEMBL22912818 0.88 KDM4E (0.62) MAPTMEN1KMT2APOLBPABPC1
SCHEMBL29396688 0.88 KDM4E (0.62) MAPTMEN1KMT2APOLBPABPC1
SCHEMBL29397055 0.82 PARP1 (0.48) MAPTMEN1KMT2APOLBPABPC1
SCHEMBL28686826 0.82 PARP1 (0.48) MAPTMEN1KMT2APOLBPABPC1
SCHEMBL25912269 0.80 MAPT (0.46) MAPTMEN1KMT2APOLBPABPC1
SCHEMBL29396402 0.79 PARP1 (0.50) MAPTMEN1KMT2APOLBPABPC1
SCHEMBL24282029 0.79 PARP1 (0.50) MAPTMEN1KMT2APOLBPABPC1
SCHEMBL29790297 0.78 KDM4E (0.76) MAPTMEN1KMT2APOLBPABPC1
SCHEMBL14474322 0.76 ALDH1A1 (0.54) MAPTMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250221987-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) 2025-07-10 — — US disclosed
WO-2025011494-A1 CRYSTAL FORM OF PIPERAZINO RING-CONTAINING DERIVATIVE, SALT FORM, PREPARATION METHOD, AND USE 优领医药科技(香港)有限公司 2025-01-16 — — WO disclosed
EP-4464704-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Acerand Therapeutics (Hong Kong) Limited (HK) 2024-11-20 — — EP disclosed
WO-2023134647-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 优领医药科技(香港)有限公司 2023-07-20 — — WO disclosed
WO-2023134647-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 优领医药科技(香港)有限公司 2023-07-20 — — WO disclosed
CN-116425744-A Piperazine-containing ring derivative, pharmaceutically acceptable salt thereof, and preparation method and application thereof 优领医药科技(香港)有限公司 2023-07-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250221987-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF PARP1, PARP11, PARP15 MAPT 1472/4885MEN1 2779/4885KMT2A 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback